PDL BioPharma, Inc. (NASDAQ:PDLI)went down by -0.97% from its latest closing price when compared to the 1-year high value of $3.89 and move down -27.54%, while PDLI stocks collected +5.17% of gains with the last five trading sessions. Press Release reported on 11/14/19 that PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
PDL BioPharma, Inc. (NASDAQ:PDLI) Worth an Investment?
PDL BioPharma, Inc. (NASDAQ: PDLI) The 36 Months beta value for PDLI stocks is at 0.69, while of the analysts out of 0 who provided ratings for PDL BioPharma, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $3.00 which is -$0.05 below current price. PDLI currently has a short float of 11.42% and public float of 110.99M with average trading volume of 1.58M shares.
PDLI Market Performance
PDLI stocks went up by 5.17% for the week, with the monthly jump of 22.98% and a quarterly performance of 20.55%, while its annual performance rate touched 6.27%. The simple moving average for the period of the last 20 days is 5.77% for PDLI stocks with the simple moving average of 1.42% for the last 200 days.
PDLI Stocks 20.64% Far from 50 Day Moving Average
After a stumble in the market that brought PDLI to its low price for the period of the last 52 weeks, PDL BioPharma, Inc. was unable to take a rebound, for now settling with -21.59% of loss for the given period.
The stock volatility was left at 4.78%, however, within the period of a single month, the volatility rate increased by 4.16%, while the shares surge at the distance of +5.54% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +29.79% upper at the present time.
In the course of the last 5 trading sessions, PDLI went up by +5.17%, which changed the moving average for the period of 200 days to the total of -5.28% of losses for the stock in comparison to the 20-day moving average settled at $2.89. In addition, PDL BioPharma, Inc. saw 5.17% in overturn over the period of a single year with a tendency to cut further gains.
PDLI Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at PDL BioPharma, Inc. (PDLI), starting from PDL BIOPHARMA, INC., who bought 6,666,667 shares at the price of $4.50 back on Jun 10. After this action, Rushing now owns 13,333,334 shares of PDL BioPharma, Inc., valued at $30,000,002 with the latest closing price.
PDLI Stock Fundamentals
The current profitability levels are settled at +34.48 for the present operating margin and +67.55 for gross margin. The net margin for PDL BioPharma, Inc. stands at -34.76. Total capital return value is set at 7.03, while invested capital returns managed to touch -7.58. Equity return holds the value 0.10%, with 0.10% for asset returns.
Based on PDL BioPharma, Inc. (PDLI), the company’s capital structure generated 17.08 points for debt to equity in total, while total debt to capital is set at the value of 14.59. Total debt to assets is settled at the value of 12.93 with long-term debt to equity ratio rests at 5.62 and long-term debt to capital is 17.08.
EBITDA value lies at 637.42 M with total debt to EBITDA carrying the value of 1.48. The value for Enterprise to Sales is 0.77 with debt to enterprise value settled at 0.82. The receivables turnover for PDL BioPharma, Inc. is 2.30 with the total asset turnover at the value of 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.86.